Our science plays well with others.
We believe that the best way to move forward, to advance our own scientific platform and the work that comes from it, is through partnerships with leading researchers and institutions. Because good company leads to good science.
Our science believes in a team approach.
At Signum, we think great ideas should be shared. So we work with a number of leading researchers and institutions to advance our programs, our ideas, and the scientific foundation of our platform.
Jeffry B. Stock, PhD at Princeton University
Signum has extensive ongoing interaction with the Research laboratory of Jeffry Stock, Ph. D., in the Dept. of Molecular Biology. Signum licensed its foundational PP2A and AFC technology from Dr. Stock’s laboratory which
continues to do basic research to elucidate the underlying biochemistry of these systems. Dr. Stock’s laboratory has been able to perform various sophisticated tests on some of Signum’s active agents, and continues to be a source of knowledge and expertise.
Donald C. Lo, PhD at Duke University
Dr. Lo is Co-Director of the Center for Drug Discovery at Duke University. His work focuses on translating basic neuroscience research into identification of novel therapeutics for neurodegenerative disorders. Application of high content screening techniques in intact neural tissues forms the cornerstone of his works in the areas of Huntington’s, Alzheimer’s and Parkinson’s diseases.
New York State Institute For Basic Research In Developmental Disabilities
In collaboration with Khalid Iqbal, Ph. D., a pioneer in Alzheimer’s neurofibrillary degeneration Professor and Chairman, Department of Neurochemistry, at the NY State Institute for Basic Research, Dr. Iqbal’s lab is exploring the effects of our STMs in various rate and mouse models in Alzheimer’s.
M. Maral Mouradian, M.D., Rutgers-Robert Wood Johnson Medical School
M. Maral Mouradian, M.D., is the William Dow Lovett Professor of Neurology and Director of the Center of Neurodegenerative and Neuroimmunologic Diseases at the Rutgers – Robert Wood Johnson Medical School. She was named the chief editor for “Neurotherapeutics” and her work focuses on the molecular pathogenesis of Parkinson’s disease and follows an extensive career that has led to the development of important therapeutics for treatment of this disease.
Signum has received grant funding from federal and research foundation sources that have allowed critical advancement of our science and validate its importance.
Angus C. Narin, Ph. D., Yale University
Dr. Narin is the Charles B.G. Murphy Professor of Psychiatry and Professor of Pharmacology at Yale School of Medicine. He is an expert in the structure and function of protein kinases and phosphatases. His particular interests have focused around dopamineric signal transduction with implications for a broad range of neurological conditions including Parkinson’s disease, schizophrenia and ADHD.
The National Institutes Of Health (NIH)
The National Institutes of Health (NIH) is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
Signum partners with some of the top skincare and cosmetics companies in the world to bring breakthrough science to the skin of millions..
Nerium International, LLC, headquartered in Addison, Texas, is a relationship marketing company that markets breakthrough products validated by science. Since its August 2011 launch, Nerium has reached record-breaking sales and earned industry accolades while building millions of consumer fans along the way. Led by an award-winning executive team with more than 200 years of collective industry experience, Nerium is committed to developing and distributing anti-aging products that are rooted in real science, produce real results, and improve consumers’ lives. Our partnership will contribute to Nerium International’s strategic goals and future products to be developed utilizing Signum’s technologies and research capabilities. We look forward to a productive, long-term relationship.
Rohto is a Japan-based company that manufactures and sells a wide range of products including skincare, eye care, and oral medicines. Headquartered in Osaka, Rohto has 20 subsidiaries and five associated companies, giving them broad reach in the Japanese markets. We jointly develop new applications and products with Rohto’s RVK (Research Village Kyoto) facility. Our partnership includes a semi-exclusive license for Arazine™ in Japan only. In addition Rohto has made a significant investment into Signum and have a seat on our Board of Directors. We will continue to contribute to Rohto’s strategic goals, while enhancing the commercial, business development and market focus of Signum’s technologies.
We have partnered with Dermata Therapeutics, LLC , a private specialty pharmaceutical company developing innovative prescription drugs for dermatological conditions. We have out-Licensed SIG-990 (aka DMT200/DMT210) to Dermata Therapeutics for the topical treatment of rosacea. SIG-990 (aka DMT200/DMT210) is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG-990 (aka DMT200/DMT210) has been cleared by the U.S. Food and Drug Administration (FDA) and SIG-990 (aka DMT200/DMT210) is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG-990 (aka DMT200/DMT210) and is responsible for the clinical development of the product. Dermalogix will receive milestone payments and royalties on revenues of the product.
We have partnered with Elizabeth Arden, Inc., on an exclusive global license for the cosmetic functional ingredient Arazine™ (N-acetyl-S-farnesyl-cysteine) as well as developing new screening methodologies to measure the anti-oxidant potential of other product ingredients. Arazine™ was recently launched as a key ingredient in Elizabeth Arden’s Prevage® Anti-aging + Intensive Repair Daily Serum product. We look forward to collaborating with Elizabeth Arden’s efforts in producing innovative, high quality skin care products supported with robust scientific data.